Document:

Non-Employee Director Compensation Arrangements

 Exhibit 10.56 
 JAZZ PHARMACEUTICALS, INC. 
 NON-EMPLOYEE DIRECTOR 
 COMPENSATION ARRANGEMENTS 
 (as
modified on August 14, 2008) 
 On May 1, 2007, the Board of Directors (the “Board”) of Jazz Pharmaceuticals, Inc.
(the “Company”) adopted the following compensation program for non-employee directors of the Board to be effective upon the closing of the initial public offering of the Company’s common stock (the
“Offering”). Pursuant to this program, each member of the Board who is not an employee or an officer of the Company will receive the following cash compensation for Board services (“Board Retainers”),
as applicable: 
  

	 	•	 	 a $30,000 annual retainer for service as a Board member; 

  

	 	•	 	 a $15,000 supplemental annual retainer for service as chair of the audit committee; 

  

	 	•	 	 a $10,000 supplemental annual retainer for service as chair of the compensation committee; and 

  

	 	•	 	 a $5,000 supplemental annual retainer for service as chair of each other committee of the Board. 

 The Company will continue to reimburse its non-employee directors for their reasonable expenses incurred in attending meetings of the Board and
committees of the Board. 
 Additionally, members of the Board who are not employees or officers of the Company will receive non-statutory
stock options under the Company’s 2007 Non-Employee Directors Stock Option Plan which will become effective immediately upon the signing of the underwriting agreement for the Offering. Each non-employee director joining the Board after the
closing of the Offering will automatically be granted a non-statutory stock option to purchase 30,000 shares of common stock with an exercise price equal to the then fair market value of the Company’s common stock. On the first trading day on
or after August 15 of each year, commencing on August 15, 2007, each non-employee director will automatically be granted a non-statutory stock option to purchase 10,000 shares of common stock on that date with an exercise price equal to
the then fair market value of the Company’s common stock. The initial grants will vest with respect to one-third of the shares on the first anniversary of the date of grant, and the balance in a series of 24 successive equal monthly
installments thereafter. The annual grants will vest in a series of 12 successive equal monthly installments measured from the date of grant. All stock options granted under the Company’s 2007 Non-Employee Directors Stock Option Plan will have
a maximum term of ten years. 
 On July 18, 2007, the Board determined that the Board Retainers for the periods from
(i) June 1, 2007 through August 14, 2007 (in an amount equal to 20.83% of the annual Board Retainer) and (ii) August 15, 2007 through August 14, 2008 shall be deemed earned and payable on August 15, 2007 and that
commencing August 15, 2008, Board Retainers for each annual period from August 15 to the next subsequent August 14 shall be deemed earned and payable in advance on August 15. Payments of Board Retainers are subject to a
non-employee’s director’s election pursuant to the Company’s Directors Deferred Compensation Plan. Any amounts deferred under the Directors Deferred Compensation Plan are credited to a phantom stock account. On August 14, 2008,
the Board determined that any distributions from a Board member’s phantom stock account shall be in shares of the Company’s common stock. 
 On December 18, 2007, the Board determined that for purposes of non-employee directors that are appointed or elected other than on August 15 of any given year, a pro-rata portion of all Board Retainers for the period from such
non-employee director’s appointment or election to the next subsequent August 15 shall be deemed earned and payable on the date of the first regularly scheduled meeting of the Board that takes place not less than 31 days following the date
of such non-employee’ director’s appointment or election provided such date is in a “window period” (as such term is defined in the Company’s Policy Regarding Stock Trading By Officers, Directors and other Designated
Employees), or in the event such date is not in a window period, the next subsequent date which is in a window period.Amendment No. 2 to License Agreement

 Exhibit 10.77 
 AMENDMENT NO. 2 TO LICENSE AGREEMENT 
 This Amendment No. 2 to License Agreement (the
“Amendment”) is made and entered into as of the 17th day of October, 2008 (“Effective Date”), by and between SOLVAY PHARMACEUTICALS, INC., a Georgia corporation having its principal office at 901 Sawyer Road, Marietta,
Georgia 30062 (“Solvay”) and JPI COMMERCIAL, LLC, a Delaware limited liability corporation and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc., a Delaware corporation (“Jazz Pharmaceuticals”), having its principal
offices at 3180 Porter Drive, Palo Alto, California 94304 (“JPI”). Solvay and JPI are referred to herein on occasion separately as a “Party” or together as the “Parties”. Capitalized terms used herein shall have their
respective meanings set forth in the License Agreement, unless otherwise defined herein. 
 WHEREAS, Solvay and Jazz Pharmaceuticals entered into that certain License Agreement (the “Agreement”) dated as of the 31st day
of January, 2007, as amended on March 12, 2008; 
 WHEREAS, in accordance with Section 13.8 of the Agreement, Jazz Pharmaceuticals
assigned the Agreement to JPI, it wholly-owned subsidiary, pursuant to that certain Assignment and Assumption Agreement dated March 17, 2008; 
 WHEREAS, Jazz Pharmaceuticals and JPI have entered into that certain LUVOX CR® License Agreement dated March 17, 2008 whereby Jazz Pharmaceuticals has the exclusive right to develop, make, have made, use and sell LUVOX CR in the Territory; and 
 WHEREAS, the Parties wish to amend the Agreement in accordance with Section 13.6 of the Agreement to change the times when certain payments are due
from JPI to Solvay; 
 NOW, THEREFORE, in consideration of the mutual covenants and promises set forth in this Amendment, the Parties agree as follows:

 1. Amendment of Definitions. 
 (a)
Section 1.11 of the Agreement is amended and replaced in its entirety with the following: 
 “1.11 Milestones” means
the events identified in Sections 3.1 (b) through (l).” 
 (b) Section 1.12 of the Agreement is amended and replaced in its
entirety with the following: 
 “1.12 “Milestone Payments” means the payments to be made by JPI to Solvay pursuant to
Sections 3.1 (b) through (l).” 

 2. Amendment of Section 3.1. Section 3.1 of the Agreement is amended and replaced in its entirety with
the following: 
 “3.1 Upfront Payment and Milestone Payments. As consideration for the license granted by Solvay to JPI
hereunder, JPI will make the following upfront and milestone payments to Solvay: 
 (a) Two million ($2,000,000.00) dollars to be paid as a
non-refundable payment at the Time of Closing (the “Upfront Payment”); 
 (b) Two million ($2,000,000.00) dollars within fifteen
(15) days of the First Commercial Sale of LUVOX-IR, supplied by or on behalf of Solvay, by Jazz Pharmaceuticals; 
 (c) Ten million
dollars ($10,000,000.00) within thirty (30) days after receipt of FDA approval of the first indication for the LUVOX CR NDA; 
 (d) Ten
million dollars ($10,000,000.00) within thirty-nine (39) days after receipt of FDA approval of the first indication for the LUVOX CR NDA; 
 (e) Three million five hundred thousand dollars ($3,500,000.00) on October 20, 2008; 
 (f) Three million five hundred thousand
dollars ($3,500,000.00) on November 15, 2008; 
 (g) Three million five hundred thousand dollars ($3,500,000.00) on December 15,
2008; 
 (h) One million one hundred sixty-six thousand six hundred and sixty-seven dollars ($1,166,667.00) on the 15th day of each month
starting on January 15, 2009 and ending on September 15, 2009; 
 (i) [ * ] dollars payable as set forth in Section 3.5 after
twelve (12) months of uninterrupted supply of Jazz Pharmaceuticals’ requirements of LUVOX CR by Elan to Jazz Pharmaceuticals in accordance with the terms and conditions of the Elan Agreement as measured from the date of the First
Commercial Sale of LUVOX CR by Jazz Pharmaceuticals; 
 (j) [ * ] dollars payable as set forth in Section 3.5 when Net Sales of LUVOX CR
first reach one hundred million ($100,000,000.00) dollars in a single twelve month period; 
 (k) [ * ] dollars payable as set forth in
Section 3.5 when Net Sales of LUVOX CR first reach two hundred million ($200,000,000.00) dollars in a single twelve month period; and 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 (l) [ * ] dollars payable as set forth in Section 3.5 when Net Sales of LUVOX CR first reach four
hundred million ($400,000,000.00) dollars in a single twelve month period. 
 Each Milestone Payment, other than those set forth in Section 3.1(h),
shall be made only once, regardless of how many times each related Milestone is achieved. No payment shall be owed for a Milestone which is not reached. 
 3. Amendment of Section 11.2. Section 11.2 of the Agreement is amended and replaced in its entirety with the following: 
 “11.2 Termination for Breach. This Agreement may be terminated by either Party in the event the other Party breaches its obligation(s) under this Agreement and does not cure the same within sixty (60) days following written
notice of such breach; provided, however, that if the breach is of such a nature that it cannot be cured within sixty (60) days, then the time to cure shall be extended until such breach can reasonably be cured. Notwithstanding the foregoing,
Solvay may terminate this Agreement immediately if any Milestone Payment required pursuant to Sections 3.1(e) through (h) is not paid within fifteen (15) days after such Milestone Payment became due and payable.” 
 4. No Other Changes. Except as set forth above, the Agreement remains in full force and effect as originally executed. 
 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 2 to License Agreement to be executed by their duly authorized representatives as of the Effective
Date. 
  

									
	JPI COMMERCIAL, LLC	 		 	SOLVAY PHARMACEUTICALS, INC.
					
	By:	 	/s/ Robert Myers	 		 	By:	 	/s/ Murray Kay
	Print Name:	 	Robert Myers	 		 	Print Name:	 	Murray Kay
	Title:	 	President	 		 	Title:	 	Vice President, Finance
	Date:	 	10/17/08	 		 	Date:	 	10/13/08

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]